PR85835

MUMBAI, India and LONDON, Sept. 29, 2020 /PRNewswire=KYODO JBN/ --

    A landmark study published in the American Association of Cancer Research's

(AACR) prestigious journal 'Cancer Prevention Research' has shown that it is

possible to identify healthy individuals with higher risk of cancer based on a

simple blood draw. The study reports that seemingly normal, asymptomatic

middle-aged men and women with no history of cancer but having detectable

clusters of Circulating Tumor Cells (abbreviated as 'C-ETACs') in their blood

have a 230 times higher one year risk of developing cancer as compared to

individuals where such clusters were undetectable in blood samples.

    In this multi-institutional international collaborative study

(https://doi.org/10.1158/1940-6207.CAPR-20-0322 ) led by Datar Cancer Genetics,

the investigators screened more than 10,000 asymptomatic individuals for

detection of C-ETACs and subsequently followed up on these individuals over a

period of one year. Simultaneously, blood from more than 4000 cancer patients

with various malignancies ('solid organ cancers') was also studied. The study

findings revealed that C-ETACs were almost invariably found in cancer patients

(> 90%) but were extremely rare (<5%) in normal individuals with no diagnosis

or symptom of cancer. Subsequently, over a one-year follow-up, 3.475% of C-ETAC

positive normal individuals were diagnosed with various cancers as opposed to

0.015% of C-ETAC negative individuals thus yielding a 230-fold increase in one

year risk of cancer diagnosis.

    The study is significant because early detection of cancer and risk

stratification of seemingly normal individuals remains an ongoing public health

challenge. 9.6 million individuals worldwide succumb to cancer each year mainly

because of late detection and even the World Health Organization in its 2014

Report has identified early detection as its major objective.

    The C-ETAC detection technology and the test are developed by Datar Cancer

Genetics using an innovative approach for selective destruction of non-cancer

cells in the blood for harvesting C-ETACs. The accuracy of the test is 95.6%

and covers more than 20 cancers including Breast, Lung, Ovarian, Stomach,

Pancreatic, Colon and Prostate.

    Commenting upon the results, Dr Tim Crook, Medical Oncologist at Broomfield

Hospital, UK and one of the authors of the paper said that 'C-ETACs are virtually

a non-invasive micro-biopsy that will enable high confidence screening and risk

stratification of seemingly normal individuals. The technology represents a major

advancement for early detection of cancer. The large size of the study is significant.'

    The research is published online

(https://doi.org/10.1158/1940-6207.CAPR-20-0322 ) .

    About Datar Cancer Genetics

    Datar Cancer Genetics (https://datarpgx.com/) is a leading cancer research

corporation specialising in non-invasive techniques for better diagnosis,

treatment decisions, and management of cancer. The Company's state-of-the-art

cancer research centre is ILAC - NABL, ISO, CAP and CLIA – USA accredited.

    For More Information contact

    Dr Vineet Datta - drvineetdatta@datarpgx.com  

    Access Publication of the study at

    https://doi.org/10.1158/1940-6207.CAPR-20-0322   

    https://datarpgx.com/publications/ 

    Website

    datarpgx.com

         Logo:

https://mma.prnewswire.com/media/1086492/Datar_Cancer_Genetics_Logo.jpg 

    Source: Datar Cancer Genetics